Filing Details
- Accession Number:
- 0001193125-21-043666
- Form Type:
- 13G Filing
- Publication Date:
- 2021-02-16 09:16:51
- Filed By:
- Sb Investment Advisers (uk) Ltd
- Company:
- Relay Therapeutics Inc. (NASDAQ:RLAY)
- Filing Date:
- 2021-02-16
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| SVF Pauling (Cayman) Limited | 0 | 27,904,963 | 0 | 27,904,963 | 27,904,963 | 31.0% |
| SoftBank Vision Fund (AIV M | 0 | 27,904,963 | 0 | 27,904,963 | 27,904,963 | 31.0% |
| SB Investment Advisers (UK) Limited | 0 | 27,904,963 | 0 | 27,904,963 | 27,904,963 | 31.0% |
Securities and Exchange Commission
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
Pursuant to § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Relay Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
75943R102
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 75943R102 | Schedule 13G | Page 1 of 8 |
| 1 | Names of Reporting Persons
SVF Pauling (Cayman) Limited | |||||
| 2 | Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
| |||||
| 3 | SEC Use Only
| |||||
| 4 | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 | Sole Voting Power
0 | ||||
| 6 | Shared Voting Power
27,904,963 | |||||
| 7 | Sole Dispositive Power
0 | |||||
| 8 | Shared Dispositive Power
27,904,963 | |||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
27,904,963 | |||||
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Not Applicable | |||||
| 11 | Percent of Class Represented by Amount in Row 9
31.0% | |||||
| 12 | Type of Reporting Person
CO | |||||
| CUSIP No. 75943R102 | Schedule 13G | Page 2 of 8 |
| 1 | Names of Reporting Persons
SoftBank Vision Fund (AIV M2) L.P. | |||||
| 2 | Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
| |||||
| 3 | SEC Use Only
| |||||
| 4 | Citizenship or Place of Organization
Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 | Sole Voting Power
0 | ||||
| 6 | Shared Voting Power
27,904,963 | |||||
| 7 | Sole Dispositive Power
0 | |||||
| 8 | Shared Dispositive Power
27,904,963 | |||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
27,904,963 | |||||
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Not Applicable | |||||
| 11 | Percent of Class Represented by Amount in Row 9
31.0% | |||||
| 12 | Type of Reporting Person
PN | |||||
| CUSIP No. 75943R102 | Schedule 13G | Page 3 of 8 |
| 1 | Names of Reporting Persons
SB Investment Advisers (UK) Limited | |||||
| 2 | Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
| |||||
| 3 | SEC Use Only
| |||||
| 4 | Citizenship or Place of Organization
England and Wales | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 | Sole Voting Power
0 | ||||
| 6 | Shared Voting Power
27,904,963 | |||||
| 7 | Sole Dispositive Power
0 | |||||
| 8 | Shared Dispositive Power
27,904,963 | |||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
27,904,963 | |||||
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Not Applicable | |||||
| 11 | Percent of Class Represented by Amount in Row 9
31.0% | |||||
| 12 | Type of Reporting Person
FI | |||||
| CUSIP No. 75943R102 | Schedule 13G | Page 4 of 8 |
| ITEM 1. (a) | Name of Issuer: |
Relay Therapeutics, Inc. (the Issuer)
| (b) | Address of Issuers Principal Executive Offices: |
399 Binney Street, 2nd Floor
Cambridge, MA 02139
| ITEM 2. (a) | Name of Person Filing: |
Each of the following is hereinafter individually referred to as a Reporting Person and collectively as the Reporting Persons. This statement is filed on behalf of:
SVF Pauling (Cayman) Limited (SVF Pauling)
SoftBank Vision Fund (AIV M2) L.P. (AIV M2)
SB Investment Advisers (UK) Limited (SBIA UK)
| (b) | Address or Principal Business Office: |
The address for SVF Pauling is c/o Walkers Corp Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The address for AIV M2 is 251 Little Falls Drive, Wilmington, DE 19808. The address for SBIA UK is 69 Grosvenor Street, London W1K 3JP, United Kingdom.
| (c) | Citizenship of each Reporting Person is: |
SVF Pauling is organized under the laws of the Cayman Islands. AIV M2 is organized under the laws of Delaware. SBIA UK is organized under the laws of England and Wales.
| (d) | Title of Class of Securities: |
Common stock, par value $ 0.001 per share (Common Stock).
| (e) | CUSIP Number: |
75943R102
| ITEM 3. |
Not applicable.
| CUSIP No. 75943R102 | Schedule 13G | Page 5 of 8 |
ITEM 4. Ownership.
(a-c)
The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of November 10, 2020, based upon 89,984,775 shares of Common Stock outstanding.
| Reporting Person | Amount beneficially owned | Percent of class: | Sole power to vote or to direct the vote: | Shared power to vote or to direct the vote: | Sole of: | Shared power to dispose or to direct the disposition of: | ||||||
| SVF Pauling (Cayman) Limited | 27,904,963 | 31.0% | 0 | 27,904,963 | 0 | 27,904,963 | ||||||
| SoftBank Vision Fund (AIV M2) L.P. | 27,904,963 | 31.0% | 0 | 27,904,963 | 0 | 27,904,963 | ||||||
| SB Investment Advisers (UK) Limited | 27,904,963 | 31.0% | 0 | 27,904,963 | 0 | 27,904,963 |
SVF Pauling is the record holder of the shares of Common Stock reported herein.
SVF Pauling is a wholly owned subsidiary of AIV M2. SBIA UK has been appointed as alternative investment fund manager (AIFM) and is exclusively responsible for managing AIV M2 in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of AIV M2, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of AIV M2s investments.
| ITEM 5. | Ownership of Five Percent or Less of a Class. |
Not applicable.
| ITEM 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
Not applicable.
| ITEM 7. | Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company. |
Not applicable.
| ITEM 8. | Identification and Classification of Members of the Group. |
Not applicable.
| ITEM 9. | Notice of Dissolution of Group. |
Not applicable.
| CUSIP No. 75943R102 | Schedule 13G | Page 6 of 8 |
| ITEM 10. | Certification. |
Not applicable.
| CUSIP No. 75943R102 | Schedule 13G | Page 7 of 8 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 16, 2021
| SVF Pauling (Cayman) Limited | ||
| By: | /s/ Karen Ellerbe | |
| Name: | Karen Ellerbe | |
| Title: | Director | |
| SoftBank Vision Fund (AIV M2) L.P. | ||
| By: | SB Investment Advisers (UK) Limited, its Manager | |
| By: | /s/ Brian Wheeler | |
| Name: | Brian Wheeler | |
| Title: | General Counsel | |
| SB Investment Advisers (UK) Limited | ||
| By: | /s/ Brian Wheeler | |
| Name: | Brian Wheeler | |
| Title: | General Counsel | |
| CUSIP No. 75943R102 | Schedule 13G | Page 8 of 8 |
LIST OF EXHIBITS
| Exhibit No. | Description | |
| 99 | Joint Filing Agreement. | |